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This document aims to support the appropriate prescribing of benzodiazepines and z-drugs (BZRA) in 
Ireland. It contains information on initiation and review of BZRA, highlighting the potential dangers 
associated with long-term use and provides examples of resource materials which may support 
prescribers and pharmacists to manage the withdrawal of patients from these medicines. This 
guidance includes the changes made by the Misuse of Drugs Regulations 2017 (including 2020 
amendment) which have replaced the now revoked Misuse of Drugs Regulations 1988, as amended.  
It is anticipated that the adoption of this guidance by prescribers will lead to a reduction in the long-
term inappropriate prescribing of these medicines. 
 
2. Scope 
This document will focus on the use of BZRA as sedatives, hypnotics and anxiolytics in adults and will 
consider only oral medicines licensed for these indications which are reimbursed in Ireland. There are 
currently twelve benzodiazepines and two z-drugs which are licensed for the treatment of anxiety 
and/or insomnia available on the Health Service Executive (HSE)-Primary Care Eligibility and 
Reimbursement Service (PCERS) reimbursable list.1 These benzodiazepines are alprazolam, 
bromazepam, chlordiazepoxide, clobazam, diazepam, flurazepam, lorazepam, lormetazepami, 
nitrazepam, prazepam, temazepam and triazolam, and the z-drugs are zolpidem and zopiclone.  
 
The use of benzodiazepines in the treatment of epilepsy, spasticity and other neurological and 
musculoskeletal disorders is outside the scope of this guidance. The safety and efficacy of BZRA for 
the treatment of anxiety and insomnia have not been established in children and adolescents below 
the age of 18 years and therefore their use is not recommended. Specialist advice should be sought 
before prescribing in this group of patients.  
 
The information in this document is relevant to prescribers [i.e. General Practitioners (GPs), Registered 
Nurse Prescribers (RNPs), Non-Consultant Hospital Doctors (NCHDs) and Consultants]. The 
information will also be useful for Pharmacists and other Healthcare Professionals working in both 
Primary Care and Acute Hospital settings.  
                                                          
i The marketing authorisation holder, Bayer Ltd, has notified the Health Products Regulatory Authority (HPRA) of 
its decision to withdraw noctamid® (lormetazepam) from the Irish Market on 9 March 2020.2 Noctamid® 
(lormetazepam) will remain on the HSE-PCERS reimbursable list until the expiry date of the last batch and 






The term benzodiazepine receptor agonist (BZRA) is used in this document when discussing both 
benzodiazepine and z-drugs in combination. When the agents are being discussed individually the 
terms “benzodiazepines” and “z-drugs” will be used.  
The term hypnotic is often used to describe medications that induce sleep. The z-drugs and some 
benzodiazepines may also be referred to as hypnotics in this document.  
 
4. Benzodiazepines and z-drugs 
4.1 Benzodiazepines 
Benzodiazepines are a class of psychoactive drugs which act on the central nervous system (CNS) to 
enhance the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A 
receptors in the brain. The various subtypes of benzodiazepine receptors have slightly different 
actions, Alpha 1 is responsible for sedative effects, Alpha 2 for anxiolytic effects and Alpha 1, Alpha 2 
and Alpha 5 for the anticonvulsant effects.3 Benzodiazepines can be used in the treatment of a number 
of conditions depending on their potency, duration of action and receptor site affinities. Some of these 
therapeutic areas include treatment of insomnia, anxiety, addiction, agitation and neurological 
disorders. Benzodiazepines are also widely prescribed in the treatment of muscle spasticity, 
involuntary movement disorders, detoxification from alcohol, and anxiety associated with 
cardiovascular or gastrointestinal conditions.4 In the late 1970s, benzodiazepines were the most 
commonly prescribed drugs worldwide.5 
 
4.1.1 Difficulties arising from the use of benzodiazepines 
There are various problems associated with benzodiazepine use including: 
 misuse  
 dependency 
 diversion 
 driving impairment 
 morbidity and mortality related to overdose and withdrawal 
 tolerance.6,7 
Older people are more vulnerable to the CNS depressant effects of benzodiazepines and their use has 




Dependence to benzodiazepines is recognised as a significant risk in patients receiving treatment for 
longer than one month.7 Continuing treatment may only assist in preventing withdrawal symptoms 
which include headache, tremor, insomnia and anxiety.11   
Before prescribing a benzodiazepine, prescribers should check whether the person might have a 
tendency to misuse drugs or alcohol, or a history of same and referral to a specialist addiction service 
should be considered in this instance.12 Drug-related behaviours may be a feature in some patients 
who are prescribed benzodiazepines. These may include diversion of valid prescriptions, illicit sale or 
use in manners alternate to the prescribed dosage, route and frequency.6 The United Nations Office 
on Drugs and Crime (UNODC) monitor the international use of illicit drugs and misuse of prescription 
medications. In their World Drug Report (2012), it noted that benzodiazepines were the main 
substances of concern in the class of CNS depressants, having largely replaced barbiturates.13 
In Ireland, the National Drug-Related Deaths Index (NDRDI), a census of drug-related deaths and 
deaths among drug users, was established by the Health Research Board (HRB). The NDRDI reports on 
poisoning deaths (also known as overdose) by alcohol and/or other drugs, and on non-poisoning 
deaths, which are deaths among drug users as a result of medical reasons or trauma.14 The HRB 
published data relating to the NDRDI from 2008 to 2017. In 2017, it reported 376 poisoning deaths 
and it noted the following:  
 prescription and/or over-the-counter drugs were implicated in two in every three (67%) 
poisoning deaths; 
 benzodiazepines were the most common prescription group implicated in poisoning deaths; 
 diazepam was the most common benzodiazepine drug implicated in 90 (24%) of all poisoning 
deaths; and 
 alprazolam poisoning deaths increased by 34% from 47 in 2016 to 63 in 2017.14,15 
 
Polydrug use is a significant risk factor for poisoning deaths; 58% of poisoning deaths were due to a 
combination of drugs in 2017, with an average of four different drugs taken. Benzodiazepines were 
the most common prescription drug group implicated in polydrug deaths. 
 89% of deaths where methadone was implicated and 86% of deaths where heroin was 
implicated involved other drugs mainly benzodiazepines. 
 All diazepam-related poisoning deaths (90) and alprazolam-related poisoning deaths (63) 





4.1.2 Pharmacology of benzodiazepines 
Benzodiazepines can be categorised as short-, intermediate- or long-acting depending on how quickly 
they are eliminated from the body. There are conflicting estimates of elimination half-lives between 
different resources. A consensus statement on the use of benzodiazepines in specialist mental health 
services by the College of Psychiatry of Ireland (CPI) (2012) places benzodiazepines into the three 
categories (short-, intermediate-, and long-acting) as outlined in table 1.12 
 
Table 1: Duration of action of certain benzodiazepines 
Short-acting Intermediate-acting Long-acting 
Triazolam (1.5 - 5.5 hours) Alprazolam     (10 - 12 hours) Chlordiazepoxide         (6 - 30 hours) 
 Lorazepam       (12 hours) Diazepam                      (up to 48 hours) 
Nitrazepam      (24 hours) Flurazepam                   (3 - 133 hours)* 
Temazepam     (7 - 11 hours)  
Bromazepam  (20 hours) 
Clobazam        (36 hours) 
( ): Half-life as per Summary of Product Characteristics 
*active metabolites: approximately 3 hours for flurazepam and N1-hydroxyethyl-flurazepam & 19 - 133 hours 
for N1-desalkyl-flurazepam. Elderly subjects (66 - 85 years) had half-lives of between 71 - 289 hours. 
 
 
The British National Formulary (BNF) classifies benzodiazepines into two categories (short-acting and 
sustained action) with lorazepam, lormetazepam and temazepam classified as short-acting and 
alprazolam, chlordiazepoxide, clobazam, diazepam, flurazepam and nitrazepam classified as having a 
sustained action.16  
 
The differences in the pharmacokinetic properties of the various benzodiazepines are relevant to 
clinical practice:   
 short-acting compounds are more suitable for older people whereas the longer-acting 
compounds may build up over time. This reduced drug clearance in older people may, in part, 
be responsible for increased susceptibility to adverse events in this patient group, the 
possibility of which is reduced by using shorter-acting alternatives;12  
 short-acting compounds are more likely to become habit forming or create dependency;12 
 benzodiazepines with an intermediate half-life result in fewer problems compared with short-
acting alternatives when used for a short period;17 and 
 compounds with half-lives of more than six hours (e.g. nitrazepam, diazepam) may be present 
in the brain the following day which may result in “hangover” effects such as sedation and an 






Z-drugs comprise of the non-benzodiazepine hypnotics: zolpidem and zopiclone. A third z-drug, 
zaleplon (Sonata®) had its marketing authorisation withdrawn in the European Union on 3 July 2015. 
The withdrawal was at the request of the marketing authorisation holder, Meda AB, who notified the 
European Commission of its decision to permanently discontinue the marketing of the product for 
commercial reasons.19 
Z-drugs differ structurally from benzodiazepines however they have the same pharmacological 
properties. Like benzodiazepines, they are GABA receptor agonists and therefore enhance GABA-
mediated neuronal inhibition.20 Z-drugs were developed with the intention of overcoming some of the 
disadvantages of benzodiazepines e.g. next-day sedation, dependence and withdrawal.11,20 However 
no clear evidence of differences in effects between z-drugs and short-acting benzodiazepines has been 
uncovered.11,20 
 
4.2.1 Difficulties arising from the use of z-drugs 
In common with the benzodiazepines, the sedative effects of the z-drugs may persist the next day.  
Tolerance, dependence and withdrawal symptoms can also occur.21,22  Zopiclone was implicated in 42 
of the 376 poisoning deaths in Ireland in 2017.14 
 
4.2.2 Pharmacology of z-drugs 
Zolpidem, an imidazopyridine, has a short half-life (mean of 2.4 hours).21 Zopiclone, a cyclopyrrolone, 
has a longer half-life (approximately 5 hours).22 This difference in half-life is relevant to clinical practice 
(see section 7.3.1). 
 
5. Legislative requirements relating to BZRA 
5.1 Misuse of Drugs Regulations 2017 
A controlled drug (CD) is any substance, product or preparation specified in a Schedule of the Misuse 
of Drugs Act 1977.23 These substances, products or preparations, including certain medicines are 
either known to be, or have the potential to be, dangerous or harmful to human health, including 
being liable to misuse or causing social harm. Ireland is required to control substances under the 
Misuse of Drugs legislation, on foot of obligations as a party to the United Nations Convention on 





The Misuse of Drugs Regulations 2017, made under the Misuse of Drugs legislation, regulate the 
import, export, manufacture, production, prescribing, supply, possession and administration of CDs.24 
A person may not possess a controlled substance unless allowed to do so under the Misuse of Drugs 
Regulations, or if the substance in question is exempt from such control under an Exemption Order.  
 
The Misuse of Drugs Regulations categorise CD substances into five schedules (ranging from the most 
tightly controlled in Schedule 1 to the least tightly controlled in Schedule 5). Schedule 4 is divided into 
Part 1 and Part 2. The update to the Regulations (2017) has significant implications for BZRA. The 
benzodiazepines which were previously exempt from this legislation have been added to Schedule 4 
Part 1 along with z-drugs zopiclone and zolpidem. The benzodiazepine temazepam remains in 
Schedule 3.  
As a result of these changes the restrictions in place on the possession of CDs will apply to all BZRA. 
Table 2 outlines examples of medicines in each of the Schedules (1-5) of the Misuse of Drugs 
Regulations 2017. 
 
Table 2: Examples of controlled drugs in Schedules 1, 2, 3, 4, or 5 of the Misuse of Drugs Regulations 
2017 
Schedule Examples of medicines in this schedule* 
Schedule 1 Substances not ordinarily used as medicines e.g. Raw Opium, Coca Leaf 
Schedule 2 Opiate substances e.g. Morphine, Fentanyl and Oxycodone 
Some stimulants e.g. Lisdexamphetamine 
Schedule 3 Certain benzodiazepines and painkillers  
e.g. Temazepam, Pentazocaine and Ketamine 
Schedule 4 Part 1 Most BZRA e.g. Diazepam, Alprazolam, Zolpidem and Zopiclone 
(see table 3) 
Schedule 4 Part 2 Certain anti-epileptics e.g. Phenobarbitone <100mg 
Certain monoamine oxidase inhibitors e.g. Selegiline 
Schedule 5 Lower strengths of painkillers e.g. Codeine (below specified concentration)  
*This list is not exhaustive (refer to legislation for comprehensive list).  
Adapted from the Medical Council and Pharmaceutical Society of Ireland Joint Guidance: Safe Prescribing and 






BZRA are classified in Schedule 3 and Schedule 4 Part 1. Table 3 classifies BZRA licensed for the 
treatment of anxiety and/or insomnia according to their CD schedule under the Misuse of Drugs 
Regulations 2017. 
Table 3: Controlled drug classification of BZRA licensed for the treatment of anxiety and/or insomnia 
Drug Schedule 3 Schedule 4 Part 1 
Alprazolam   
Bromazepam   
Chlordiazepoxide   
Clobazam   
Diazepam   
Flurazepam   
Lorazepam   
Lormetazepam   
Nitrazepam   
Prazepam   
Temazepam   
Triazolam   
Zolpidem   
Zopiclone   
 
The Medical Council and Pharmaceutical Society of Ireland (PSI) developed Joint Guidance on ‘Safe 
Prescribing and Dispensing of Controlled Drugs’ (2017) which includes the legal requirements for 
prescribing and dispensing BZRA.25 This guidance also highlights the importance of good 
communication between healthcare teams involved in the prescribing and dispensing of BZRA. 
Table 4 details the prescription writing, dispensing and storage requirements for BZRA (Schedule 3 










Table 4: Prescription writing, dispensing and storage requirements for Schedule 3 and Schedule 4 Part 1 BZRA24,25 















Specific criteria to be included 
which must be handwritten by the 
prescriber¥ on the prescription 
 
-Name of the drug (brand or generic name) 
-Dose 
-Pharmaceutical form 
-Strength (where appropriate) 
-Total quantity in both words (e.g. five) and 
figures (e.g. 5) 
 
Specific criteria to be included 
which is not required to be 
handwritten on the prescription 
-Name and address of the patient* 
-Name of the prescriber (including first 
name) 
-Address of the prescriber† 
-Prescriber contact number 
-Prescriber occupation 
-Prescriber registration number 
 
-Name and address of the patient* 
-Name of the prescriber (including first name) 
-Address of the prescriber† 
-Prescriber contact number 
-Prescriber occupation 
-Prescriber registration number 
 
-Name of the drug 
(brand or generic name) 
-Dose 
-Pharmaceutical form 
-Strength (where appropriate) 
-Total quantity in both words (e.g. five) and figures 
(e.g. 5) 




















Requirement for prescription to be 
first dispensed within 14 days of 
date written on prescription 
Yes No 
Can prescription be repeated? No Yes 
Instalments Where a prescription is to be dispensed in 
instalments, the prescription must contain 
a direction specifying the number of 
instalments and the intervals at which the 
instalments may be dispensed. 
Where a prescription is to be dispensed in 
instalments, the prescription must contain a 
direction specifying the number of instalments and 























At the time of supply: mark on the 
prescription the date on which the drug is 
supplied. 
Where the prescription has been endorsed as being 
repeatable i.e. where it may be dispensed on more 
than one occasion and where a prescription is 
dispensed in part, the person who dispensed the 
prescription shall record on the prescription:  
 Quantity of each controlled drug supplied 
 Date on which the supply was made 
 Name and address of the pharmacy where the 
controlled drug was supplied from. 
Where the dispensing of the drug has been 
completed, the person who dispensed it shall write 
or print prominently on the prescription the word 




The prescription shall be retained on the 
premises for two years from the date of 
supply. 
 
For a repeat prescription which is not exhausted: a 
copy of the prescription and any endorsements shall 
be retained on the premises for two years from the 
date of supply.  
For a prescription which is exhausted: it shall be 
endorsed and retained on the premises for two 
years. 
Safe custody Required to be stored in a safe. Not required to be stored in a safe. 
 ¥Refer to section 5.1.1 Misuse of Drugs (Amendment) Regulations 2020 for temporary change to this requirement 
*An addressograph (sticker with patient name and address) does not fulfil the requirement for this information 
to be indelible 
†unless a Health Prescription which is a prescription issued in connection with arrangements made under section 
59 of the Health Act 1970 upon a form supplied by or on behalf of a health board i.e. GMS prescriptions. However, 




To ensure adherence to the prescribing requirements for BZRA in the hospital setting, the patient’s 
name and address must be handwritten on discharge prescriptions. An addressograph (sticker with 
the patient’s name and address) will not fulfil the legislative requirements. 
 
5.1.1 Misuse of Drugs (Amendment) Regulations 2020 
In April 2020, temporary amendments to the Medicinal Products (Prescription and Control of Supply) 
Regulations 2003 and the Misuse of Drugs Regulations 2017 were made by the Minister for Health, in 
response to the outbreak of COVID-19. These temporary provisions are designed to ensure that 
patients can continue to access their ongoing treatment and regular medicines during the ongoing 
public health emergency and to assist in easing the additional burdens on prescribers and pharmacists 
arising from the pandemic. The Misuse of Drugs (Amendment) Regulations 2020 are available on 
www.gov.ie 
 
The PSI, Medical Council and HSE have published Guidance for prescribers and pharmacists on 
legislation changes to facilitate the safe supply of medicines during the COVID-19 pandemic (April 




Key Changes under the amendments relating to BZRAii  
 Electronic Prescription Transfer 
The amendments allow for the electronic transfer of prescriptions including those for BZRA between 
doctors and pharmacies and removes the need for a paper equivalent. 
o Where a Schedule 3 BZRA (temazepam) is prescribed using the national electronic prescription 
transfer system, the prescription writing requirements still apply, however, these do not need 
to be in the prescriber’s own handwriting. 
 
 Validity period of prescriptions 
o The maximum period of validity of a prescription for a Schedule 4 Part 1 BZRA is 9 months 
from the date specified on the prescription (previously 6 months). This is only when in the 
pharmacist’s professional judgement, after consultation with the patient, and if needs be the 
prescriber, that continued treatment is required and it is safe and appropriate to do so. 
                                                          
ii PSI, Medical Council & HSE. Guidance for prescribers and pharmacists on legislation changes to facilitate the 




o The validity of a prescription for a Schedule 3 BZRA (temazepam) remains at 14 days i.e. a 
supply cannot be made later than 14 days after the date on the prescription. The validity of a 
prescription for a Schedule 3 BZRA to be dispensed in instalments is also unchanged i.e. the 
first instalment must be dispensed within 14 days of the date stated on the prescription and 
no instalment shall be supplied later than 2 months after the date specified on the 
prescription.  
 
 Emergency Supply (at the request of a prescriber) 
Under the amendments, a pharmacist is permitted to supply a Schedule 3 and Schedule 4 Part 1 BZRA 
at the request of a prescriber where:  
o it is unreasonable at the time of supply, in the circumstances arising from the COVID-19 
emergency, for the person to obtain a new prescription for that medicinal product,  
o it is the opinion of the pharmacist that it is safe, appropriate and necessary for the continued 
treatment of the person for an emergency supply to be made, and 
o no greater quantity of the product than will provide 5 days’ treatment is supplied.  
A prescriber can also request an emergency supply in the circumstances arising from the COVID-19 
emergency of the following Schedule 4 Part 1 BZRA for the treatment of epilepsy: midazolam, 
clobazam and clonazepam. Legislation does not limit the quantity of these CDs that may be supplied 
at the request of a prescriber in these circumstances, however, the pharmacist should be satisfied that 
the quantity requested is safe and appropriate for the patient at that point in time. 
Where a prescriber makes a request for an emergency supply for their patient, they must undertake 
to provide the prescription to the pharmacy within 72 hours. 
 
 Emergency Supply (at the request of a patient) 
Under the amendments, a pharmacist can dispense at the request of a patient an ‘emergency supply’ 
of: 
o Up to 5 days’ supply of a Schedule 3 or 4 Part 1 BZRA where it is unreasonable at the time of 
supply, in the circumstances arising from the COVID-19 emergency, for the person to obtain 
a new prescription for that medicinal product and it is the opinion of the pharmacist that it is 
safe, appropriate and necessary for the continued treatment of the person for an emergency 
supply to be made. 
o Up to 10 days’ supply of the following Schedule 4 Part 1 BZRA for the treatment of epilepsy: 




5.2 Road Traffic Act 
The side-effects of BZRA include sedation, impaired concentration and alertness which can cause 
driving impairment. In Ireland, it is an offence to:  
(1) drive under the influence of drugs (including prescribed drugs) where driving is impaired to such 
an extent that one doesn’t have proper control of the vehicle; 
(2) drive under the influence of three specified drugs; cannabis, cocaine and heroin (regardless of 
driving performance) above specified levels.26 
 
The Medical Bureau for Road Safety (MBRS) have been testing Irish drivers for the presence of drugs 
since 1999. Recently, the Road Traffic Act 2016 has given Gardaí new powers to conduct ‘Preliminary 
Drug Testing’ at the roadside or in Garda stations.27 It involves testing a sample of a driver’s saliva for 
the presence of cannabis, cocaine, opiates and benzodiazepines. If positive, a blood specimen can be 
taken which will be sent to the MBRS for evidential testing. Patients are advised to follow the advice 
provided by their doctor and/or pharmacist when taking any medicines and to always read the patient 
information leaflet to check whether the medicine can affect ability to drive. The Road Safety 











Anxiety is an unpleasant emotional state characterised by feelings of fear and frequently involving 
distressing physical/somatic symptoms.28 Generalised anxiety disorder (GAD) is one of a range of 
anxiety disorders that include panic disorder (with and without agoraphobia), post-traumatic stress 
disorder, obsessive-compulsive disorder, social phobia, specific phobias and acute stress disorder.29 




 Counsel patients that their ability to drive safely may be reduced by BZRA. 













6.1 Non-pharmacological treatments for anxiety 
The management of anxiety conditions, however classified or caused, usually includes non-
pharmacological measures that may range from low-intensity interventions to specific psychological 
techniques which can include anxiety management training, behaviour or cognitive therapy. National 
Institute for Health and Care Excellence (NICE) guidance Generalised Anxiety Disorder and Panic 
Disorder in Adults: management (2019), recommends that a stepped-care approach is used for 
patients with GAD, commencing with non-pharmacological measures as outlined in table 5.29 
 
Table 5: Stepped-care model for people with generalised anxiety disorder29 
Focus of intervention Nature of intervention 
STEP 1: All known and suspected 
presentations of GAD 
Identification and assessment; education about GAD 
and treatment options; active monitoring 
STEP 2: Diagnosed GAD that has not 
improved after education and active 
monitoring in primary care 
Low-intensity psychological interventions: individual 
non-facilitated self-help*, individual guided self-
help and psychoeducational groups 
STEP 3: GAD with an inadequate response 
to step 2 interventions or marked 
functional impairment 
Choice of a high-intensity psychological intervention 
(cognitive behavioural therapy/applied relaxation) 
or a drug treatment 
STEP 4: Complex treatment-refractory GAD 
and very marked functional impairment, 
such as self-neglect or a high risk of self-
harm 
Highly specialist treatment, such as complex drug 
and/or psychological treatment regimens; input 
from multi-agency teams, crisis services, day 
hospitals or inpatient care 
*A self-administered intervention involving written or electronic self-help materials (usually a book or workbook), 
usually with minimal therapist contact e.g.an occasional short telephone call of no more than five minutes. 
GAD: generalised anxiety disorder 
 
Low-intensity psychological interventions which include individual non-facilitated self-help, individual 
guided self-help and psychoeducational groups are recommended as first-line interventions prior to 
drug treatment. 
Step 2 may be facilitated by provision of self-help supports and information. A resource list including 
books, online programmes and useful websites for prescribers to disseminate to patients is available 
in Appendix A.  Guidance for the encouragement of relaxation is available in Appendix C. 
Step 3 includes high intensity psychological interventions, cognitive behavioural therapy (CBT) and 





6.1.1 Counselling in Primary Care Service 
The HSE National Counselling Service (NCS) has developed a Counselling in Primary Care (CIPC) service. 
CIPC is the provision of short-term counselling in primary care settings to medical card holders aged 
18 years and over by professionally qualified and accredited counsellors/therapists who work under 
the supervision of the HSE-NCS. This counselling service is suitable for people with mild-to-moderate 
psychological problems and for those experiencing difficulties such as:  
• depression 
• anxiety 
• relationship difficulties 
• stress. 
GPs or other members of the primary care team with the GP’s awareness can refer patients. 
Information for referrers and patients along with a referral form is available on the HSE website 
www.hse.ie/eng/services/list/4/mental-health-services/counsellingpc/cipc-national-evaluation/ 
 
6.2 Pharmacological treatments for anxiety  
NICE guidance on the management of GAD and panic disorder (2019) recommends that selective 
serotonin reuptake inhibitors (SSRIs) should be offered as first-line pharmacological treatment for 
patients with GAD. Serotonin-noradrenaline reuptake inhibitors (SNRIs) may be used if there is no 
response to SSRIs. If the person cannot tolerate SSRIs or SNRIs, pregabalin can be considered.29 Irish 
College of General Practitioners (ICGP) Guidelines for the Management of Depression and Anxiety 
Disorders in Primary Care (2006), recommends SSRIs or SNRIs as first-line treatment for GAD.28 The 
SSRIs escitalopram and paroxetine, and the SNRIs duloxetine and venlafaxine are currently licensed in 









6.2.1 Role of benzodiazepines in the treatment of anxiety 
Although benzodiazepines have been used extensively as first-line pharmacological treatment of 
anxiety since the 1960s, public perception and concern for abuse liability and physical dependence 
Practice Tip 
The MMP recommends selective serotonin reuptake Inhibitors (SSRIs) as 
first-line pharmacological treatment for generalised anxiety disorder (GAD). 








with longer-term use gave rise to a great deal of controversy during the 1980s.34 The potential for  
cognitive impairment and associated dependency issues do not make them appropriate first-line 
pharmacological options.35 NICE guidance on the management of GAD and panic disorder (2019), 
recommends that benzodiazepines should not be offered for the treatment of GAD in primary or 
secondary care except as a short-term measure during crises.29 The 2006 ICGP guidelines also 
recommends benzodiazepines only as short-term adjunctive therapy in severe anxiety.28 A consensus 
paper by the CPI on the use of benzodiazepines in specialist mental health services (2012), 
recommends that benzodiazepines should not be used as first-line treatment but reserved as an 
option for treatment-resistant cases.12 
 
6.2.2 Benzodiazepines licensed to treat anxiety  








        
Licensed doses and maximum treatment durations for benzodiazepines in the treatment of anxiety as 
per SmPC are detailed in Appendix D.  
 
6.2.3 Recommended duration of use  
Benzodiazepines should be restricted to short-term use during crises when the event is disabling and 
severe resulting in significant distress or problems in social functioning.43 ICGP Guidelines for the 
Management of Depression and Anxiety Disorders in Primary Care (2006), recommend 
benzodiazepines as adjunctive therapy for a maximum of two weeks.28 Similarly the consensus paper 
by the CPI (2012) recommend a short-term treatment duration (2 - 4 weeks) to reduce the risks of 
dependence and tolerance.12 Patients should be assessed regularly and the need for continued 
treatment should be evaluated.36-42 The Royal Australian College of General Practitioners (RACGP) 
Prescribing drugs of dependence in general practice (2015), recommends that patients being 
prescribed benzodiazepines should obtain all prescriptions from the same doctor so their risk of 










Insomnia is a disturbance of normal sleep patterns commonly characterised by difficulty in initiating 
sleep (sleep-onset insomnia) and/or difficulty maintaining sleep (sleep maintenance).20 Patterns of 
sleep vary greatly between people. Before a hypnotic medication is prescribed the underlying cause 
of the insomnia should be established and, where possible, underlying factors should be treated.16 
 
7.1 Types of Insomnia 
Transient insomnia can occur in individuals who normally sleep well and sleep disturbance may be 
due to extraneous factors such as increased noise, shift work and jet lag.16 
Short-term insomnia is usually related to an emotional issue or medical illness. It may last for a few 
weeks and may recur whereas chronic insomnia can develop due to psychiatric disorders such as 
anxiety, depression, and abuse of drugs and alcohol.16 
Sleep-onset insomnia is characterised as difficulty initiating sleep while continuous sleep disturbance 
is characterised by ongoing sleep disturbance during the night. 
The management of insomnia will differ depending on the duration of the problem (short-term versus 
chronic) and the type of insomnia (sleep-onset versus continuous). 
 
7.2 Non-pharmacological treatments for insomnia 
Before prescribing a hypnotic, the underlying cause of the insomnia should be identified and treated 
if possible.16,20 Patients should be provided with information which may help overcome their insomnia 
including: 
o the normal amount of sleep varies widely and usually decreases with age; 
o temporary sleep problems are common at times of stress or physical illness; 
o alcohol may help in falling asleep, but can lead to restless sleep; and 
o stimulants (including tea and coffee) can cause or worsen insomnia. 
Practice Tip 
The MMP recommends benzodiazepines should be prescribed for the shortest possible 







The American College of Physicians (ACP) guideline Management of Chronic Insomnia Disorder in 
Adults (2016), recommends that all adult patients receive CBT for insomnia as the initial treatment for 
chronic insomnia disorder.45 CBT for insomnia consists of a combination of treatments that include 
cognitive therapy around sleep, behavioural interventions (e.g. sleep restriction and stimulus control) 
and education (e.g. sleep hygiene).45 These non-pharmacological measures should be trialled before 
prescribing hypnotics (see table 6).20,46 
 
Table 6: Non-pharmacological interventions for the treatment of insomnia46 
Intervention Intended effect 
Sleep hygiene Reduce behaviours that interfere with sleep drive or that increase 
arousal 
Sleep restriction Increase sleep drive and stabilise circadian rhythm 
Stimulus control Reduce arousal in sleep environment and promote the association 
between bed and sleep 
Cognitive therapy Restructure maladaptive beliefs regarding health and daytime 
consequences of insomnia 
Relaxation therapy Reduce physical and psychological arousal in sleep environment 
 
Good sleep hygiene should be recommended to patients suffering from insomnia to make them more 
aware of behavioural, environmental, and temporal factors that may be affecting sleep.47 Patient 
guides for the encouragement of good sleep behaviour (The Good Sleep Guide) and relaxation (The 
Good Relaxation Guide) are available in Appendix B & C respectively and can be made available to 







7.3 Pharmacological treatments for insomnia 
7.3.1 Role of BZRA in the treatment of insomnia 
BZRA should be prescribed for short periods of time only, in strict accordance with their licensed 
indications for the management of severe insomnia after consideration of the use of non-
Practice Tip 
The MMP recommends ‘The Good Sleep Guide’ as a first-line treatment for 





pharmacological measures.20  Benzodiazepines should be used to treat insomnia only when it is severe, 
disabling, or causing extreme distress.16 Similarly the z-drugs, zopiclone and zolpidem, are licensed for 
the short-term treatment of insomnia which is severe, debilitating or subjecting the individual to 
extreme distress.21,22 
NICE issued technology appraisal guidance (TA77) regarding the use of z-drugs in the short-term 
management of insomnia (2004).20 The guidance concluded that there was a lack of compelling 
evidence to distinguish between z-drugs (zaleplon, zolpidem, zolpiclone) or the shorter-acting 
benzodiazepine hypnotics. 
NICE guidance recommends only switching from one z-drug to another if a patient experiences side-
effects that are directly related to the specific z-drug. Patients who have not responded to one of 
these hypnotic drugs should not be prescribed any of the others.20 
In general, long-acting benzodiazepine hypnotics should not be prescribed.43 If prescribed, they tend 
to have next-day residual effects causing psychomotor impairment and affecting mental function.20 
Short- or intermediate-acting benzodiazepines can be prescribed for patients with sleep-onset 
insomnia while patients experiencing continuous sleep disturbances or early awakening may require 
a benzodiazepine with an intermediate half-life.43 
Zolpidem should only be prescribed to patients with sleep-onset insomnia as it is not effective at 
maintaining sleep due to its short half-life. Zopiclone may be prescribed for patients with continuous 














    Practice Tips for the Pharmacological Treatment of Insomnia 
 Avoid long-acting benzodiazepine hypnotics. 
 Zolpidem should only be prescribed for patients with sleep-onset insomnia. 





7.3.2 BZRA licensed to treat insomnia 
BZRA licensed for the treatment of insomnia are listed in table 7. 
Table 7: BZRA licensed for the treatment of insomnia21,22,40,41,48-52 
 
*Insomnia associated with anxiety          
 
Licensed doses and maximum treatment durations for BZRA in the treatment of insomnia as per SmPC 
are detailed in Appendix D. 
 
7.3.3 Recommended duration of use 
Hypnotics should not be prescribed indiscriminately and routine prescribing is undesirable; they 
should be reserved for short courses in the acutely distressed.16 The Department of Health (DoH) Good 
Practice Guidelines for prescribing benzodiazepines (2002) recommend that hypnotic benzodiazepine 
prescriptions be limited to between 2 - 4 weeks.43 The licensed duration of treatment for hypnotic 
benzodiazepines is a few days to a two-week period, with a maximum duration of four weeks including 
the tapering off process (see Appendix D).  
The SmPC for zolpidem and zopiclone state that treatment duration should be as short as possible.21,22 
The duration of treatment should usually vary from a few days to two weeks, with a maximum of four 
weeks including the tapering off process where clinically appropriate.21,22  
It may be useful to inform the patient when treatment is initiated that it will be of a limited duration. 
In certain cases with BZRA, extension beyond the maximum treatment period may be necessary; this 















 Practice Tip 
The MMP recommends that BZRA should only be prescribed for a period of a  









8. Safety concerns with the use of BZRA  
When used appropriately BZRA can be effective for the short-term management of acute severe 
anxiety or insomnia. However, long-term use of BZRA is associated with problems such as tolerance, 
dependence and withdrawal symptoms.16,21,22,36-42,48-52 Patients should be made aware of the 
possibility of rebound phenomena to minimise anxiety should such symptoms develop when the BZRA 
is discontinued.11 Repeat BZRA prescriptions should not be issued without consultation. 
 
8.1 Side-effects 
BZRA side-effects include: 
 psychomotor impairment and increased risk of motor vehicle accidents and falls53 
 impairment in judgement and dexterity17 
 forgetfulness, confusion, irritability, aggression and paradoxical disinhibition.17,22 
These side-effects may also occur with short-term use.17 Unwanted side-effects can largely be 
prevented by prescribing low dosages and courses of short duration in suitable patients.12 
 
8.2 Tolerance  
With long-term use, BZRA lose the ability to increase the effect of GABA, resulting in the need to take 
higher doses to achieve a similar effect.17 Tolerance to BZRA progressively reduces their effectiveness 
for the treatment of insomnia or anxiety.17 Tolerance develops at different rates and degrees for the 
various actions.4 
 
Tolerance to the hypnotic effects of benzodiazepines develops rapidly, usually within days or weeks 
of regular use while tolerance to the anxiolytic effects develops more slowly, over months.5 Long–
term efficacy of benzodiazepines is unreliable, particularly the hypnotics where tolerance to their 
effects can develop within 3 - 14 days of continuous use.16 
 
8.3 Dependence 
The World Health Organisation (WHO) describes dependence syndrome as a cluster of physiological, 
behavioural, and cognitive phenomena in which the use of a substance or class of substances takes a 
much higher priority for the user than other behaviours that once had greater value.54 
Dependence is a significant risk in patients receiving treatment for longer than one month which the 
prescriber should be conscious of when evaluating the relative benefits and risks of continued 
prescribing.7 Psychological and physical dependence can develop within a few weeks or months of 





Benzodiazepine dependence can present in a number of different ways including:17,55 
 patients “need” benzodiazepines to carry out normal day-to-day activities 
 patients continue to take benzodiazepines even though the original indication for the 
prescription is no longer relevant 
 patients have difficulty in stopping treatment or reducing the dosage due to withdrawal 
symptoms 
 patients become anxious if their next prescription is not readily available 
 patients may increase the dosage from that in the original prescription. 
 
8.4 Safety concerns in special patient populations 
8.4.1 Older people 
The National Healthcare Quality Reporting System Annual Report (2019) highlighted that Ireland has 
the highest rate of chronic BZRA prescriptions (≥ 365 defined daily doses in one year) in patients aged 
65 years and older compared to 15 other Organisation for Economic Co-operation and Development 
(OECD) countries. In Ireland, approximately 78 per 1,000 older people receive long-term prescriptions 
for BZRA compared to an average of 25 per 1,000 across the OECD countries.56 
 BZRA should not be routinely prescribed in older people; if required they should be used at 
the lowest dose and with caution, as side-effects are likely to be enhanced e.g. sedation, 
disturbance of gait, falls, daytime drowsiness, cognitive impairment, hypotension, memory 
impairment and reduced psychomotor performance.8,9,10,16 
 Shorter half-life benzodiazepines are usually recommended for older adults (less 
accumulation and more rapid clearance); however they may be associated with a clinically 
significant discontinuation syndrome and have higher potential for abuse.57 
 A meta-analysis has shown that BZRA use in older people is associated with an increased risk 
of hip fractures. Patients who are newly prescribed BZRA are at the greatest risk.58 
 Benzodiazepine use has also been associated with an increased risk of Alzheimer’s disease in 
older people.59 A case-control study showed an increased risk of Alzheimer’s disease in older 
patients who were previously treated for more than three months with a benzodiazepine. The 
risk was higher with long-acting benzodiazepine use compared to short-acting benzodiazepine 
use.59  
 New benzodiazepine use in older people has been associated with an increased risk of 





8.4.2 Pregnancy  
 Specialist advice should be sought before prescribing benzodiazepines in pregnancy:16 
o benzodiazepines and metabolites cross the placenta and accumulate in foetal circulation;61,62 
o it is advisable to avoid in the first trimester due to the risks of teratogenicity (association with 
incidence of cleft palate);62 and 
o prolonged use of benzodiazepines in pregnancy is associated with low birth weight and in the 
third trimester may result in floppy baby syndrome.17 There is some evidence to suggest a 
link with congenital abnormalities such as cleft lip or palate, pyloric stenosis and alimentary 
tract atresia.17,61,63 
 
 Z-drugs should not be prescribed during pregnancy.17 
 
8.4.3 Hepatic and renal impairment  
 
Prescribing in hepatic impairment 
 BZRAs are not indicated in patients with severe hepatic insufficiency as they may precipitate 
encephalopathy.16,22 
 In general, manufacturers advise caution and dose reduction in mild-to-moderate hepatic 
impairment; benzodiazepines with a shorter half-life are considered safer.16  
 
Prescribing in renal impairment 
 There is increased cerebral sensitivity to BZRA in patients with renal impairment.16 
 
 
8.5 Safety advice issued in relation to benzodiazepines and opioids 
In March 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a reminder 
that opioids co-prescribed with BZRA can produce additive CNS depressant effects, thereby increasing 
the risk of sedation, respiratory depression, coma, and death.64 Healthcare professionals are advised 
to only co-prescribe BZRA and opioids if there is no alternative. If a decision is made to co-prescribe, 
the lowest possible doses should be given for the shortest duration and patients should be monitored 
for signs of respiratory depression. 
 
8.6 Resources to raise public awareness of the potential harm associated with BZRA 
In July 2020, resources were developed for prescribers and pharmacists by the HSE in collaboration 




(ONMSD) and the Nursing and Midwifery Board of Ireland (NMBI) to raise public awareness of the 
potential harm associated with BZRA. 
 
The resources include: 
 Insomnia and Anxiety Medicines- Patient Guide  
 Insomnia and Anxiety Medicines- poster for prescriber practice 
 Insomnia and Anxiety Medicines- poster for pharmacy. 
 
The patient guide includes information on BZRA, the potential harms associated with their use, and 








9. Good Practice Guidelines 
Good practice guidelines on benzodiazepine prescribing issued by the DoH (2002) in response to a 
report of the Royal College of Psychiatrists Benzodiazepines: risks, benefits or dependence (1997), 
stress the significant risk of dependence in patients receiving treatment for longer than one month.7 
The guidelines recommend that every clinician examine the benefit: risk ratio in each individual case 
early in treatment and recommend that benzodiazepines should not be prescribed for longer than one 
month in the treatment of anxiety and should be limited to between 2 - 4 weeks in the treatment of 
insomnia or sleep disturbance.43   
In the case of benzodiazepines used to treat insomnia, it may be useful to inform patients that 
treatment will be of a limited duration when initiated. Patients should be made aware of the possibility 
of rebound insomnia thereby minimising anxiety over such symptoms should they occur on 
discontinuation of the benzodiazepine.43 
 
   Practice Tip  
To reduce the risk of side-effects, tolerance and dependence with BZRA, only 
prescribe low doses and courses of short duration for acute severe symptoms in 








Before prescribing a benzodiazepine, the prescriber should: 
 Take a full history including alcohol, and licit and illicit drug history 
 Inform the patient of the side-effect profile of benzodiazepines and offer an information 
leaflet  
 Consider and treat, if possible any underlying causes 
 Consider referral to other services 
 Consider alternative therapies 
 Consider delaying prescribing until a subsequent visit.43 
 
The guidelines outline good practice for prescribers when prescribing benzodiazepines for the first 
time and when prescribing for dependent patients (see table 8).   
Table 8: Good practice guidelines for prescribing benzodiazepines43 
        Prescribing for the first time Prescribing for dependent patients 
Initiate with the lowest dose and adjust 
according to response 
 
Issue small quantities at a time 
Do not prescribe for longer than four weeks 
 
Review regularly, usually monthly 
Use phased dispensing where appropriate Ensure all patients are made aware of the risks of 
long-term benzodiazepine use and document this 
 
Record all details of medication prescribed 
and duration of treatment 
Encourage all patients with dependency to withdraw 
and offer them detoxification programmes at regular 
intervals and document all communications 
 
 
9.1 Practice audit 
Good practice guidelines on benzodiazepine prescribing from the CPI recommend conducting regular 
audits of practice.12 Standards of practice should ensure short-term use of benzodiazepines, and 
reasons for continuing prescribing beyond this term should be documented.12 The ICGP have 
developed an audit tool for the prescribing of benzodiazepines (2019) which is available at:65 
www.icgp.ie/audit  
 
The HSE-PCERS provides regular prescribing reports to GPs based on dispensed drug data for BZRA on 
the General Medical Services (GMS) scheme. While this data is not a comprehensive analysis of all 
prescribing (e.g. private and Drug Payment scheme prescriptions are not included) it can be used as a 





Figure 1: Sample BZRA prescribing analysis report – PCERS 
Figure 1 explanatory notes: 
Prescribing frequency is outlined in the first table where:  
- Panel is the number of patients on your panel in the age group presented 
- # is the number of unique patients to whom a BZRA has been dispensed 
- Qty is the total quantity of BZRA i.e. the actual number of tablets/capsules dispensed 
- % is the percentage of patients in the age category who have received a BZRA 
The traffic light column in the first table highlights your prescribing rate compared to the national 
mean prescribing rate (represented by standard deviation) at an age group level. Standard deviation 
is a measure of dispersion or variation in a set of data from its mean. Green represents prescribing 
that is lower than or within one standard deviation higher than the national mean prescribing rate. 
Yellow represents a prescribing rate between one and two standard deviations higher than the 
national mean prescribing rate. Red represents a prescribing rate that is more than two standard 
deviations higher than the national mean prescribing rate.  
 
Prolonged use prescribing is outlined in the second table where:  
- # is the number of unique patients on your panel to whom a BZRA have been dispensed for 
various periods of time. The first row presents the number of patients to whom a BZRA has 
not been dispensed. 
- % is the percentage of patients on your panel who have been dispensed a BZRA for each 




to whom a BZRA has not been dispensed at all. In the example, there are 79.06% of patients 
on the panel in the reported year to whom a BZRA has not been dispensed at all.  
 
Your prescribing compared to the national norm is outlined in third section (bell curve) 
The presentation of your overall prescribing rate on this chart is on the basis of the number of standard 
deviations your prescribing rate is away from the national mean. The position of your prescribing rate 









10. Prescribing trends of BZRA in Ireland  
Analyses of the PCERS pharmacy claims were performed by the MMP to determine prescribing trends 
for BZRA in Ireland over the last number of years. 
 
10.1 Utilisation and expenditure 
Figure 2 illustrates the number of patients in receipt of benzodiazepines and z-drugs on the GMS 
scheme from January 2017 to February 2020. In January 2017, approximately 93,900 patients were in 
receipt of a benzodiazepine and 77,000 were in receipt of a z-drug on the GMS scheme. The number 
of patients in receipt of benzodiazepines decreased to approximately 85,700 in January 2020 while 
the number of patients in receipt of a z-drug decreased slightly to 76,100. 
 
         Practice Tips 
   The MMP recommends that prescribers: 
 Carry out a documented review of BZRA prescriptions regularly. 
 Inform patients of the risk of dependency with long-term use of BZRA 












Figure 2: Number of patients in receipt of benzodiazepines and z-drugs on the GMS scheme (January 
2017- February 2020)66 
 
The four most commonly prescribed BZRA on the GMS scheme in 2019 were zopiclone, zolpidem, 










































































































Zopiclone and zolpidem were the most frequently prescribed medicines of all BZRA on the GMS 
scheme in 2019 while diazepam and alprazolam were by far the most commonly prescribed 
benzodiazepines. 
In 2019, total expenditureiii on BZRA on the GMS scheme was approximately €19.27 million with the 
z-drugs zopiclone and zolpidem accounting for €8.96 million of this figure (see figure 4).66 
 
 
Figure 4: Total expenditure on individual BZRA on the GMS scheme in 201966 
 
 
10.2 Duration of use 
Further analysis of the duration of use of BZRA for the 12 months of 2019 was performed. Patients 
who initiated BZRA in January 2019 or February 2019 (and had not received a BZRA in the previous 6 
months) were followed up to the end of 2019.iv Over 15,000 patients initiated a prescription for a 
benzodiazepine in January or February 2019, and over 9,000 patients initiated a prescription for a z-
drug.  
The analysis demonstrated that approximately 15% of benzodiazepines and 27% of z-drugs were 
dispensed for greater than three months in this 12-month period on the GMS scheme (see figure 5).67 
                                                          
iiiTotal expenditure includes pharmacy fees and VAT where applicable 
 
ivIf the quantity supplied was >30, this was assumed to be 1 month supply at a more frequent dosing.  
The total days’ supply over the year (2019) were summed, but this was not consecutive use so an individual 














Figure 5: Duration of use of BZRA for patients initiating treatment in January or February 2019 on the 
GMS scheme.67 
 
Despite z-drugs being licensed for a maximum duration of four weeks in the treatment of insomnia, 
only 57% of patients were in receipt of z-drugs for a duration of one month or less. Approximately 
27% of patients received z-drugs for greater than 3 months during this period. The analysis of all 
benzodiazepine use on the GMS scheme showed that approximately 15% of patients were in receipt 
of a benzodiazepine for greater than 3 months in this period. While some indications for 
benzodiazepine use (e.g. epilepsy) may require long-term treatment, use in anxiety and insomnia 
should be limited to the shortest possible duration.67 
Similar analysis conducted for the 12 months of 2015 showed that approximately 17% of patients 
received benzodiazepines and 22% of patients received z-drugs for greater than 3 months.67 
 
11. Deprescribing of BZRA 
Deprescribing is the planned and supervised process of tapering, stopping, discontinuing, or 
withdrawing medicines, with the goal of managing polypharmacy and improving outcomes.68 It is an 
active review process that prompts prescribers to identify medications which are not performing 
effectively in the risk-benefit trade-off and may in fact be causing harm to the patient.69,70 The 
prevalence of ongoing BZRA use in adults presents an opportunity for the implementation of 
≤ 1 month ≤ 2 months ≤ 3 months >3, ≤6 months 
>6, ≤12 
months 
Benzodiazepines 68.88 10.11 5.74 6.14 9.13






















deprescribing strategies in this patient cohort. Patients should be regularly offered the opportunity to 
withdraw from long-term BZRA use.71 
The development of dependence can pose significant challenges when discontinuation of treatment 
with BZRA is attempted, as withdrawal symptoms often develop.70 Prescribers, pharmacists and 
patients all have a role to play in the deprescribing process. Decisions about dose and reduction should 
be made between the prescriber and patient in a collaborative and flexible manner.72 
Treatment withdrawal is possible in many patients once the issues relating to prolonged drug use are 
explained and discussed.11 Studies have shown that even minimal interventions such as a letter from 
the prescriber to targeted patients can be effective in reducing or stopping benzodiazepine use 
without adverse effects.73 Prior to initiating a withdrawal programme, prescribers may wish to inform 
their patients that their practice will be introducing this and invite them to discuss the withdrawal 
process. This will allow patients to prepare for the process. A sample letter to patients is included in 
Appendix E.   
 
Consideration should be given to whether withdrawal can be appropriately managed in the primary 
care setting.11 Specialist advice, or referral to an appropriate specialist should be considered for 
patients with a history of alcohol or other drug use or dependence, severe medical or psychiatric 
disorder or personality disorder, or a history of drug withdrawal seizures.11 
 
11.1 Approaches to deprescribing 
Withdrawal can be achieved by a number of methods. It is important, however, that it is managed 
correctly, with tapering of doses carried out gradually under the guidance of the prescriber. Abrupt 
withdrawal of a benzodiazepine may produce confusion, toxic psychosis, convulsions, or a condition 
resembling delirium tremens.16 Short-term users of benzodiazepines (2 - 4 weeks) can usually taper 
off within 2 - 4 weeks. However long-term users should be withdrawn over a much longer period of 
several months or more.16 There are two approaches to facilitate dose reduction: 
i. patients may be slowly withdrawn from their current BZRA or 
ii. patients may be switched to an equivalent dose of a long-acting slowly-metabolised 
benzodiazepine such as diazepam which is slowly tapered down.  
 
Diazepam, which has a long half-life (up to 48 hours; table 1), is often the long-acting benzodiazepine 
of choice to facilitate withdrawal as the availability of different strengths allows for small decremental 




Switching is often recommended when patients experience severe withdrawal symptoms.16 Switching 
to diazepam is best carried out gradually, usually in a step wise manner (see section 12.2). Dose 
withdrawal may be commenced when switching to diazepam is complete.11 The first switch should be 
to the night time dose to avoid sedation during the daytime.11 Tables 9 and 10 below are examples of 
equivalence tables if switching from a BZRA to diazepam to facilitate deprescribing. 
 
Table 9: Dose equivalence table if switching from current benzodiazepine to diazepam16 
Drug Dose equivalent to diazepam 5 mg 
Alprazolam 250 micrograms 
Chlordiazepoxide 12.5 mg 
Clobazam 10 mg 
Clonazepam 250 micrograms 
Flurazepam 7.5 - 15 mg 
Lorazepam 500 micrograms 
Lormetazepam 0.5 - 1 mg 
Nitrazepam 5 mg 
Temazepam 10 mg 
 
Table 10: Dose equivalence table if switching from current z-drug to diazepam72 
Drug Dose equivalent to diazepam 5 mg 
Zopiclone 7.5 mg 
Zolpidem 10 mg 
 
 
11.2 Community detoxification 
A shared-care approach with substance misuse services may be required for more complex cases. 
National Community Detoxification Benzodiazepine Guidelines have been developed by the Ana Liffey 
Drug Project for patients in a non-residential setting.72 These guidelines were developed from the 
Community Detoxification Protocols (Ana Liffey Drug Project, 2011) which were reviewed and 
amended in 2015. The Ana Liffey Drug Project is a national addiction service charity organisation. The 
organisation’s mission is to work with people affected by problem substance use and the organisations 
that assist them. The aim is to reduce harm to service users and society, and to provide opportunities 
for development of those service users and organisations. These guidelines recommend that a 
community detoxification programme should include:  
(1) a named key worker or healthcare professional who will provide psychological support, and  
(2) a prescribing GP who delivers a physical and mental health assessment, medical support and 





The guideline sets out how GPs and key workers should interact to provide effective supports while 
managing the risk of relapse and overdose. A patient’s suitability to participate in this structured 
detoxification programme is determined by the GP involved. The guidelines are available at:72 
www.drugs.ie/downloadDocs/2017/Community-Detox-Guidelines-Benzodiazepines-2017.pdf 
 
In the next section the MMP have incorporated educational resource material developed by the All 
Wales Medicines Strategy Group (2016)17 and guidance available in the BNF16 and in NICE Clinical 
Knowledge Summaries (2018)11 for the purpose of providing deprescribing support to prescribers. 
 
12. Resources to support deprescribing of BZRA 
 
12.1 Initial consultation                                                    
*Adapted with kind permission of the All Wales Medicines Strategy Group Educational Pack17 
The first consultation with the patient should cover the following points: 
 the risks associated with long-term use of BZRA e.g. tolerance, lack of effectiveness, 
dependency 
 the risks of drowsiness, falls, cognitive impairment, confusion 
 establish the reasons for sleep disturbance/anxiety 
 the withdrawal plan including the tapering process 
 advantages of reducing/stopping BZRA e.g. more refreshing sleep, alertness 
 the possibility of withdrawal symptoms developing and how to deal with them 
 GP practice policy with regard to lack of adherence and lost prescriptions. 
 
12.2 Dose reduction schedules 















12.2.1 A suggested approach for managing patients who want to stop BZRA 
*Summarised from NICE Clinical Knowledge Summary: Benzodiazepine and z-drug withdrawal 11  
 Decide if the patient can reduce the dose and stop their current BZRA without switching to 
diazepam.  
 Switching to diazepam should be considered for: 
-patients on short-acting potent benzodiazepines (alprazolam and lorazepam); 
-patients using preparations that do not easily allow for small reductions in dose (alprazolam, 
flurazepam, lormetazepam); 
-patients experiencing difficulty or who are likely to experience difficulty withdrawing directly 
from temazepam, nitrazepam, or z-drugs, due to a high degree of dependency (associated 
with long duration of treatment, high doses, and a history of anxiety problems). 
 Seek specialist advice before switching to diazepam in patients with hepatic dysfunction as 
diazepam may accumulate to toxic levels in these individuals. 
 If switching patient to diazepam, carry out gradually in a stepwise manner. Consider making the 
first switch in the night-time dose to avoid day time sedation. Dose equivalences are set out in 
tables 9 and 10. Further information on switching to diazepam is available in NICE Clinical 
Knowledge Summary11. 
 Start dose withdrawal when conversion to diazepam is complete.  
 Upon dose reduction of the patient’s current BZRA or diazepam, negotiate a gradual withdrawal 
schedule which is flexible. Be guided by the patient in making adjustments so that they remain 
comfortable with the withdrawal process.  
- Dose tapering such as a 5 - 10% reduction every 1 - 2 weeks, or an eighth of the dose 
fortnightly, with a slower reduction at lower doses. The rate of reduction should take into 
account the drug, dose and duration of treatment, as well as personal circumstances.  
- Titrate dose according to severity of withdrawal symptoms. If the patient experiences 
difficulties with a dose reduction, encourage them to persevere and suggest delaying the 
next reduction. Do not revert to a higher dose. Make future dose reductions in smaller 
steps if necessary.  
- Review frequently to detect and manage problems, and to provide advice and 
encouragement. 
 
See NICE Clinical Knowledge Summary: Benzodiazepine and z-drug withdrawal for further information. 
Examples of switching schedules to diazepam and withdrawal schedules for BZRA are available in the 





12.2.2 A suggested protocol for withdrawal following long-term benzodiazepine use 
* From the BNF16 
 
 Transfer patient stepwise, one dose at a time over about a week, to an equivalent daily dose 
of diazepam (see table 9), preferably taken at night. 
 Reduce diazepam dose, usually by 1 - 2 mg every 2 - 4 weeks (in patients taking high doses of 
benzodiazepines, initially it may be more appropriate to reduce the dose by up to one-tenth 
every 1 - 2 weeks). If uncomfortable withdrawal symptoms occur, maintain this dose until 
symptoms lessen. 
 Reduce diazepam dose further, if necessary in smaller steps; steps of 500 micrograms may be 
appropriate towards the end of withdrawal. Then stop completely. 
 For long-term patients, the period needed for complete withdrawal may vary from several 
months to a year or more. 
 The addition of beta-blockers, antidepressants and antipsychotics should be avoided where 
possible. 
 Counselling can be of considerable help both during and after the taper. 
 
Provide patients with Stopping your benzodiazepine and z-drug: A guide for patients available in 
Appendix F. 
Other examples of withdrawal schedules are available in the National Community Detoxification: 
Benzodiazepine Guidelines (2016) available at:72 
www.drugs.ie/downloadDocs/2017/Community-Detox-Guidelines-Benzodiazepines-2017.pdf 
 
12.3 Withdrawal symptoms 
Benzodiazepine withdrawal syndrome may develop at any time up to three weeks after stopping a 
long-acting benzodiazepine but may occur within a day in the case of short-acting agents. It is 
characterised by insomnia, anxiety, loss of appetite and of body-weight, tremor, perspiration, tinnitus 
and perceptual disturbances. Some symptoms may be similar to the original complaint and encourage 
further prescribing; some symptoms may continue for weeks or months after stopping 
benzodiazepines.16 The severity of withdrawal symptoms depends on several factors including 
treatment duration, drug dose, drug half-life, and baseline levels of anxiety and depression.17 The risk 





12.4 Managing patients who do not want to reduce or discontinue treatment 
The following points should be considered in patients who do not want to reduce or discontinue 
treatment:  
 do not pressurise patients to reduce or discontinue use unless they are motivated to do so;11 
 listen to concerns about the strategy, explain the benefits and advantages and reassure the 
patient; 11 
 encourage even small reductions which may help the patient to realise that their fears are 
unfounded;11 and 
 encourage patients to revert if they have any change in their circumstances which might 
facilitate them undergoing withdrawal. Likewise, prescribers should be alert to the 














Although BZRA can be effective for the short-term management of a range of medical and psychiatric 
conditions, it is important to exercise caution when prescribing these medicines and to only prescribe 
them for the shortest possible duration for treatment of insomnia and anxiety. Prescribers should 
consider non-pharmacological management options for patients with insomnia/anxiety prior to 
prescribing BZRA. When prescribing BZRA, the lowest dose which controls symptoms should always 
be prescribed. Repeat prescribing should be avoided as tolerance can develop within days or weeks 
of regular use to the hypnotic effects and more slowly, over months to the anxiolytic effects. Caution 
is especially relevant when prescribing for patients with a history of substance abuse or addiction. 
Prescribers must exercise appropriate judgement and consider whether the benefits associated with 
the use of these drugs outweigh the potential risks. Prescribing of BZRA should be avoided in older 
people as they are at a greater risk of developing ataxia and confusion leading to falls and injury. 
 
     Practice Point 
     There are two approaches to deprescribing of BRZA: 
i. Withdraw slowly from current BZRA  
ii. Switch patients on a BZRA to an equivalent dose of a long-acting slowly-



































BZRA in the treatment of anxiety and insomnia 
 
 BZRA should only be initiated and prescribed at the lowest effective dose for as 
short a duration as possible. 
 Non-pharmacological management options should always be considered as 
alternatives or additions to BZRA treatment. 
 Prior to prescribing a BZRA, inform the patient of the side-effect profile of BZRA 
and offer an information leaflet. 
 Patients being prescribed BZRA should obtain all prescriptions from the same 
doctor so their risk of dependence can be monitored. 
 Repeat BZRA prescriptions should not be issued without consultation. 
 Tolerance to hypnotic effects of benzodiazepines may develop after a few days or 
weeks of regular use while tolerance to the anxiolytic effects may develop more 
slowly over months. 
 Dependence is a significant risk in some patients on treatment for longer than 
one month; consider this risk before initiating treatment. 
 Patients should be encouraged to withdraw gradually (if appropriate) after long-
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Appendix A: Suggested non-pharmacological resources for prescribers and patients 
1. Cognitive Behavioural Therapy Resource List  
 
Online Resources  
 Aware Life Skills www.aware.ie/education/life-skills-online-programme/ (over 18 years)  
or Aware: Beat the Blues (age 15-18)  
 Mood Gym Programme https://moodgym.com.au/ (cost €24 for 12 months)  
 Wellbeing http://wellbeing-glasgow.org.uk   
 Living Life to the Full www.llttf.com/    
 Self Help Booklets https://web.ntw.nhs.uk/selfhelp/ - excellent for use in Primary Care  
 
Recommended Song for Relaxation: Marconi Union – ‘Weightless’ (accessible on youtube or spotify)  
Recommended App: www.sanvello.com; Relaxation App: www.calm.com   
 
 
Overcoming Books: A self-help guide using Cognitive Behavioural Techniques  
• OVERCOMING ANGER AND IRRITABILITY  
• OVERCOMING ANOREXIA NERVOSA  
• OVERCOMING ANXIETY BULIMIA NERVOSA AND BINGE-EATING  
• OVERCOMING CHILDHOOD TRAUMA  
• OVERCOMING CHRONIC FATIGUE  
• OVERCOMING CHRONIC PAIN  
• OVERCOMING COMPULSIVE GAMBLING  
• OVERCOMING DEPERSONALIZATON AND FEELINGS OF UNREALITY  
• OVERCOMING DEPRESSION  
• OVERCOMING GRIEF  
• OVERCOMING INSOMNIA AND SLEEP PROBLEMS  
• OVERCOMING HEALTH ANXIETY  
• OVERCOMING LOW SELF-ESTEEM  
• OVERCOMING MOOD SWINGS  
• OVERCOMING OBSESSIVE COMPULSIVE DISORDER  
• OVERCOMING PANIC  
• OVERCOMING ANXIETY  
• OVERCOMING PARANOID AND SUSPICIOUS THOUGHTS  
• OVERCOMING PROBLEM DRINKING  
• OVERCOMING RELATIONSHIP PROBLEMS  
• OVERCOMING SEXUAL PROBLEMS  
• OVERCOMING SOCIAL ANXIETY AND SHYNESS  
• OVERCOMING TRAUMATIC STRESS  
• OVERCOMING WEIGHT PROBLEMS  
• OVERCOMING WORRY AND GENERALISED ANXIETY DISORDER  
• OVERCOMING YOUR CHILD’S FEARS AND WORRIES  
• OVERCOMING YOUR CHILD’S SHYNESS AND SOCIAL ANXIETY  
 
The above book titles can be bought online or in local book shops. 
 
This list offering some suggestions was kindly compiled by Marie Carey: BABCP Accredited Cognitive Behavioural 





2. YourMentalHealth.ie (www.yourmentalhealth.ie) 
YourMentalHealth.ie has practical information and advice on services and supports to take care of 
mental health. It was developed by the HSE, the National Office for Suicide Prevention and partner 
organisations. 
 
The YourMentalHealth information line is a 24- hour phone service. The service provides information 
on supports and services, and how to access them.  




  3. Support Guides for Patients
 ‘The Good Sleep Guide’ (see appendix B) 
 ‘The Good Relaxation Guide’ (see appendix C) 
 ‘Stopping your medicine: benzodiazepines and z-drugs. A guide for patients’ (see appendix F) 









Appendix B: The Good Sleep Guide* 
 
Establish a regular sleep pattern 
 Set the alarm for the same time every morning for seven days a week, at least until your sleep pattern settles 
down. 
 Get up at the same time every day, even if you did not fall asleep until late.  
 Do not sleep during the day.  
During the evening  
 Ensure you ‘put the day to rest’. Think it through and use a notebook if necessary. Tie up “loose ends” in your 
mind and plan ahead.  
 Try to keep yourself fit by performing light exercise in the late afternoon or early evening (later than this can 
disturb your sleep).  
 Have a regular routine before sleep, whereby you wind down during the course of the evening and avoid 
anything that is mentally demanding within 90 minutes of bedtime.  
 Keep your sleep for bedtime (i.e. avoid falling asleep or snoozing in the armchair).   
 Do not drink too much caffeinated substances (e.g. coffee, tea and certain soft drinks) and only have a light 
snack for supper. Try decaffeinated milk-based or herbal beverages.  
 Do not drink alcohol to aid your sleep. It may help you fall asleep, but you will almost certainly wake up during 
the night.  
 Make sure your bed is comfortable and the bedroom is not too cold (but not too warm) and is quiet (use 
earplugs if necessary).  
At bedtime  
 Go to bed when you are ‘sleepy tired’ and not before.  
 Do not read or watch TV in bed.  
 Turn the lights off when you get into bed.  
 Relax and tell yourself that ‘sleep will come when it’s ready’. Enjoy relaxing even if you don’t fall asleep at first.  
 Do not try to fall asleep. Sleep cannot be switched on deliberately but attempting to do so may switch it off!  
 
If you have problems getting to sleep  
 Try not to get upset or frustrated as sleep problems are quite common and they are not as damaging as you 
might think.  
 If you are awake in bed for more than 20 minutes, get up and go into another room.  
 Do something relaxing for a while and don’t worry about tomorrow. Read, watch television or listen to quiet 
music and after a while you should feel tired enough to go to bed again.  
 Remember that people usually cope quite well even after a sleepless night. Only return to bed when you feel 
“sleepy tired”.  
 Establishing a good sleep pattern may take a number of weeks; however, you should remain confident that 
you will achieve it by working through this guide. 
*Adapted with the kind permission of the All Wales Medicines Strategy Group Educational Pack: Material to Support Appropriate Prescribing of Hypnotics 
and Anxiolytics across Wales.17 
Other Practical Tips 
-Avoid using smart phones or other devices which emit ‘blue light’ late in the evening/night as this can disrupt normal 
sleep schedules.  
-Do not use your phone as an alarm clock; use a separate alarm clock. 
-If you need to use your phone as an alarm clock, place your phone away from sight or at the other end of the room 





Appendix C: The Good Relaxation Guide* 
 
Dealing with physical tension 
 Finding and dedicating time to relax is essential. Give relaxation some of your time, not just what’s left over. 
 Incorporate relaxing activities into your lifestyle. Do not rush tasks or try too hard to resolve issues. 
 Adopt a relaxation routine, but do not expect to learn without practice.  
 Relaxation routines are available (audio recordings) which help to relieve muscle tension and teach 
appropriate breathing exercises. 
 Try not to worry about tension symptoms, such as aches, stiffness, increased heart rate, perspiration, 
stomach churning, etc. 
 Keep fit and try adhering to a physical exercise regime. Regular brisk walks or swimming can help relieve 
tension. 
 
 Dealing with worry 
 Accept that worrying is normal and on occasion it may be useful.  
 Write down your concerns and decide which ones are more important using a rating system (i.e. marks out 
of ten). 
 Work out a plan of action for each problem.  
 Share your worries with friends, relatives or your GP, as they may provide helpful advice.  
 Mentally repeating a comforting phrase may help block out worrying thoughts. Similarly, reading, 
crosswords, hobbies and interests may all help keep your mind active and positive.  
 Enjoy quiet moments (e.g. sit and listen to relaxing music). Allow your mind to wander and try to picture 
yourself in pleasant situations.  
 
Dealing with difficult situations  
 Build your confidence by accepting and confronting circumstances that make you feel more anxious. Adopt a 
step-by-step approach to help face things and places which make you feel tense. Regular practice will help 
you overcome these issues. 
 Write a plan and decide how you are going to deal with difficult situations.  
 For further encouragement, reward yourself and share with others when you overcome difficult situations.  
 As you face difficult situations your confidence will grow and your anxiety symptoms should become less 
troublesome.  
 Everyone has good and bad days. Expect more good days as time goes on.  
 Try to put together a programme incorporating all the elements presented in ‘The Good Relaxation Guide’ 
that meets the needs of your particular situation. Remember that expert guidance and advice is available if 





*Adapted with the kind permission of the All Wales Medicines Strategy Group Educational Pack: Material to Support Appropriate Prescribing of 




Appendix D: BZRA licensed for the treatment of anxiety and insomnia- licensed dosage and duration as per SmPC 
 
Anxiety 
Benzodiazepine Dose in adults Dose in older people Licensed duration 
Alprazolam36 
  
Initially 0.5 mg - 1 mg daily in divided doses, with 
increments (no greater than 1 mg every 3 - 4 days), to 
the level of optimal control usually 3 to 4 mg daily. 
 
Initially 0.25 mg twice 
daily  
Maximum 8 - 12 weeks including a tapering off process 
Bromazepam37 3 - 18 mg daily in divided doses 
 
Half the adult dose Maximum 8 - 12 weeks including a tapering off process 
Chlordiazepoxide38 30 mg daily in divided doses 
 
Half the adult dose Maximum four weeks including a tapering off process 
Clobazam39 20 - 30 mg daily in divided doses or as a single dose 
given at night 
 
10 - 20 mg daily  Maximum 8 - 12 weeks including a tapering off process 
Diazepam40 2 mg three times daily 
Maximum dose: 30 mg daily in divided doses 
Half the adult dose Maximum 8 - 12 weeks including a tapering off process. 
Treatment should not be continued at the full dose beyond 
four weeks 
 
Lorazepam41 1 - 4 mg daily in divided doses 
 
Half the adult dose   A few days to four weeks including the tapering off process 
Prazepam42 30 mg daily in single or divided doses 
 





BZRA Drug Class Dose in adults* Dose in older people* Licensed duration 
Diazepam40 Benzodiazepine Insomnia associated with anxiety: 
5 - 15 mg  
 
Insomnia associated with anxiety: 
2.5 - 7.5 mg  
Maximum four weeks including tapering off process 
Flurazepam48 Benzodiazepine 15 - 30 mg 15 mg  Few days to two weeks, maximum four weeks including 
tapering off process 
 
Lorazepam42 Benzodiazepine Insomnia associated with anxiety: 
1 - 2 mg  
Insomnia associated with anxiety: 
0.5 - 1 mg 
Few days to four weeks including the tapering off 
process 
 
Lormetazepam†49 Benzodiazepine 1 mg 0.5 mg Few days to two weeks, maximum four weeks including 
tapering off process 
 
Nitrazepam50 Benzodiazepine 5 - 10 mg 2.5 - 5 mg Few days to two weeks, maximum four weeks including 
tapering off process 
 
Temazepam51 Benzodiazepine 10 - 20 mg 10 mg Few days to two weeks, maximum four weeks including 
tapering off process 
 
Triazolam52 Benzodiazepine 0.25 mg 
0.125 mg in patients previously 
untreated with hypnotics 
0.125 mg Few days to two weeks, maximum four weeks including 
tapering off process 
Zolpidem21 Z-drug 10 mg  5 mg Few days to two weeks, maximum four weeks including 
tapering off process 
 
Zopiclone22 Z-drug 7.5 mg 3.75 mg  
  
Few days to two weeks, maximum four weeks including 
tapering off process 
 
*Hypnotic BZRA should be taken at night. See individual SmPCs for more information on times these medicines should be taken in relation to bedtime.    
†The marketing authorisation holder, Bayer Ltd, has notified the Health Products Regulatory Authority (HPRA) of its decision to withdraw noctamid® 




Appendix E: Sample letters to patients on BZRA 
*Taken from the ICGP Substance Misuse Programme, Benzodiazepine Prescribing Sample Audit- Adapted from 
Sample letters Mercer’s Medical Centre65  
 
Practice Name and Address 
Dear Patient, 
We are currently undertaking a review of prescriptions for medications collectively known as 
benzodiazepines and sleeping tablets. I am writing to you because our records show that you have 
received a number of prescriptions for one or more of these types of medications in the past 12 
months. 
Recent studies have shown that if these medications are used for long periods of time, they can have 
harmful side-effects, including anxiety symptoms, memory and sleep problems and they can also be 
addictive. Long-term use is therefore no longer recommended.  
We are writing to ask you to consider cutting down your dose of tablets and perhaps stopping them 
completely at some time in the future. As each person is different, we would like to discuss this with 
you in person within the next 3 months.  
The best way to cut down your tablets is to take them only when you feel they are absolutely 
necessary. It is best to cut down gradually; otherwise you may have some withdrawal side-effects. 
You should not stop your tablets suddenly. Once you start to reduce your dose you may start to 
notice that you feel a lot better and you may be able to think about stopping altogether.  
Please make an appointment with your GP to discuss this further. If you have not attended to discuss 
this within the next 3 months, we may not be able to continue to prescribe this medicine for you. If 
you have already discussed this with your doctor, or have stopped your medications, this letter does 
















Our records show that you have been prescribed benzodiazepines and/or sleeping tablets on a 
regular basis over the past number of months. We wrote to you on___________ asking you to make 
an appointment with your GP to discuss these prescriptions. 
From our records I note that you have not attended for review and therefore we are no longer able 
to prescribe this medication for you. 
If you would like to discuss this matter or if our records are incorrect, please make an appointment 
with your GP to discuss. 
 


















Appendix F: Stopping your medicine: benzodiazepines and z-drugs. A guide for 
patients* 
 
What are benzodiazepines and z-drugs, and why are they used?  
Benzodiazepines are a group of medicines that can be prescribed for short periods to help with 
sleeping problems or to help with episodes of severe anxiety. Examples include temazepam and 
nitrazepam for sleeping problems, and diazepam and lorazepam for anxiety. 
 
Z-drugs act in a similar way to benzodiazepines and are used to help with sleeping problems. Examples 
of z-drugs are zolpidem and zopiclone. 
 
Benzodiazepines and z-drugs are only available on prescription and must only be taken by the person 
they were prescribed for.  
 
Benzodiazepines and z-drugs often work well for a short period of two to four weeks, but if you use 
them for longer, the medicine may lose its effect and you may become dependent on it. 
 
What are the side effects of taking benzodiazepines and z-drugs?  
Benzodiazepines and z-drugs act on the brain and may therefore:  
 affect your memory and concentration 
 make you feel confused or irritable  
 make you feel drowsy 
 make you more likely to have a fall 
 make you more likely to have an accident, either at home, work or in the car.  
 
Why should I stop taking a benzodiazepine or z-drug?  
There are many good reasons why you should stop taking your benzodiazepine or z drug: 
 If you have used it for a long time and the medicine has lost its effect, it will no longer help 
with the condition you are taking it for 
 You may become, or may have already become, dependent on it. If you stop, you will have 
fewer side effects, so you will be: 
- More alert and able to concentrate 
- Less drowsy 
- Less irritable and depressed 
- Less likely to have an accident when driving. 
 
How should I stop taking my benzodiazepine or z-drug? 
1. DO NOT stop taking your medicine suddenly 
You should discuss stopping your medicine with your doctor, pharmacist or practice nurse to 
make sure that you reduce your dose slowly. Different people will need to reduce their dose at 




process, as this will give you a better chance of long-term success. It is important that you take it 
at your own pace – one that feels right for you. 
 
2. Plan how you will reduce and stop  
Your doctor, pharmacist or practice nurse will give you advice on how you should reduce the dose 
of your medicine and help you think about other ways of dealing with your worries/sleep 
problems. Depending on which medicine you are taking, it may be easier to withdraw if you 
change to diazepam tablets. Diazepam tablets are available in a number of different strengths, 
which makes it easier to reduce your dose more slowly. Your doctor, pharmacist or practice nurse 
will let you know if you can change to diazepam and will tell you how you can reduce your dose. 
Most people find that about one to two weeks between each dose reduction works for them, but 
everyone should find their own level. 
 
3. Keep a diary 
Keeping a diary can help as it records your progress and achievements. This will give you more 
confidence and encouragement to carry on. 
 
4. Don’t go back!  
When people begin to reduce their dose, they often become more able to deal with normal day-
to-day events and may feel much better. However, it is also common to have a bad patch at some 
time during the process. If you feel you are going through a bad patch, stick with the current dose 
until you feel ready to reduce again; this may take several weeks but it is important that you take 
it at your own pace. Any reduction in dose is a step in the right direction.  
 
5. Be aware of possible side effects  
If your medicine is reduced slowly it is unlikely that you will have any side effects, but it is a good 
idea to be aware of possible side effects as they will tell you that you may need to reduce more 
slowly: 
 Aches and pains can be common when reducing the dose of benzodiazepines and z-drugs; taking 
painkillers can help you feel better.  
 Sleeping problems may occur when reducing your dose, so it is important to get some exercise 
as this can help you sleep. Try not to worry about not sleeping; the more you worry about not 
getting sleep, the less sleep you are likely to get.  
 Stomach and bowel problems, such as diarrhoea and irritable bowel syndrome may occur. These 
symptoms usually disappear after stopping the medicine completely, but you may wish to discuss 
them with your doctor or pharmacist.  
 Sinus problems can cause sinus pain; taking painkillers can help. 
 Vivid dreams and nightmares may occur. As you reduce your dose, your dreaming will return 
and although they may sometimes be disturbing, it is a sign that your sleep is returning to normal 
and that your body is re-adjusting successfully. 
 Hot flushes and shivering. The feeling of burning and extreme heat and sweating is also 




 Panic attacks can be very distressing but they are never fatal and usually last no more than 30 
minutes. Getting control of your breathing by taking slower and deeper breaths will help you feel 
less panic.  
 Anxiety may be mistaken for the condition that your medicine was prescribed for in the first 
place.  
 Agoraphobia is a type of anxiety disorder in which you fear and often avoid places or situations 
that might cause you to panic and make you feel trapped, helpless or embarrassed. Usually, as 
you continue to reduce your dose, these feelings go away. 
 




*Adapted with the kind permission of the All Wales Medicines Strategy Group Educational Pack: Material to Support 





















Appendix G: New in this update - version 1.1 
 
Scope: updated to include the withdrawal of Noctamid® (lormetazepam) 1 mg tablets from the Irish 
market. 
Section 4: Difficulties arising from the use of benzodiazepines updated to include National Drug-
Related Deaths Index (NDRDI) data 2017 (section 4.1.1). 
Section 5: Legislative requirements relating to BZRA updated to include Misuse of Drugs 
(Amendment) Regulations 2020 (section 5.1.1). 
Section 6: Pharmacological treatments for anxiety updated to include NICE Clinical guideline 113: 
Generalised Anxiety Disorder and Panic Disorder in Adults: management [2019] (section 6.2). 
 
Section 8: Safety concerns with the use of BZRA updated to include: 
 data from the National Healthcare Quality Reporting System Annual Report (2019) in 
relation to chronic BZRA use in patients aged 65 years and older (section 8.4.1), 
 safety advice issued in relation to benzodiazepines and opioids (section 8.5), and  
 resources developed to increase public awareness of the potential harm associated with 
BZRA (section 8.6). 
Section 10: Prescribing trends of BZRA in Ireland updated to include: 
 utilisation data for January 2017- February 2020 (section 10.1), 
 utilisation and expenditure data for 2019 (section 10.1), and  
 duration of use analysis for 2019 (section 10.2). 
Section 11: Deprescribing -further information included.  
Appendix A: Suggested non-pharmacological resources for prescribers and patients updated. 
 
 
 
 
